Ebb & Flow

While VCs continue to pour money into no research-development only companies, drug reprofilers and other fast track business models, at least one NRDO got some push-back from the public markets. After competing its road show and with its IPO scheduled to price last week, in-licensor Peninsula put its deal on ice after finding that portfolio managers wanted a beefier pipeline.

Outside of doripenem, a broad spectrum carbapenem antibiotic that it got from Shionogi, Peninsula does not have any other compounds in the clinic. It is conducting a Phase III trial of doripenem to treat complicated urinary tract infection (UTI), and it plans to begin two Phase III studies in the first half of the year in complicated intra-abdominal infections and hospital-acquired pneumonia. ...